1. Stem Cells and Regenerative Medicine
  2. Genetics and Genomics

Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6

  1. Rasmus O Bak
  2. Daniel P Dever
  3. Andreas Reinisch
  4. David Cruz Hernandez
  5. Ravindra Majeti  Is a corresponding author
  6. Matthew H Porteus  Is a corresponding author
  1. Stanford University, United States
https://doi.org/10.7554/eLife.27873
Share this article
Cite this article
  1. Rasmus O Bak
  2. Daniel P Dever
  3. Andreas Reinisch
  4. David Cruz Hernandez
  5. Ravindra Majeti
  6. Matthew H Porteus
(2017)
Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
eLife 6:e27873.
https://doi.org/10.7554/eLife.27873
  2. Download BibTeX
  3. Download .RIS

Abstract

Precise and efficient manipulation of genes is crucial for understanding the molecular mechanisms that govern human hematopoiesis and for developing novel therapies for diseases of the blood and immune system. Current methods do not enable precise engineering of complex genotypes that can be easily tracked in a mixed population of cells. We describe a method to multiplex homologous recombination (HR) in human hematopoietic stem and progenitor cells and primary human T cells by combining rAAV6 donor delivery and the CRISPR/Cas9 system delivered as ribonucleoproteins (RNPs). In addition, the use of reporter genes allows FACS-purification and tracking of cells that have had multiple alleles or loci modified by HR. We believe this method will enable broad applications not only to the study of human hematopoietic gene function and networks, but also to perform sophisticated synthetic biology to develop innovative engineered stem cell-based therapeutics.

Article and author information

Author details

  1. Rasmus O Bak

    Department of Pediatrics, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7383-0297

  2. Daniel P Dever

    Department of Pediatrics, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.

  3. Andreas Reinisch

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.

  4. David Cruz Hernandez

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.

  5. Ravindra Majeti

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    For correspondence
    rmajeti@stanford.edu
    Competing interests
    Ravindra Majeti, has equity and consults for Forty Seven Inc..

  6. Matthew H Porteus

    Department of Pediatrics, Stanford University, Stanford, United States
    For correspondence
    mporteus@stanford.edu
    Competing interests
    Matthew H Porteus, has equity and consults for CRISPR Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3850-4648

Funding

Danish Council for Independent Research (DFF-1333-00106B)

  • Rasmus O Bak

Danish Council for Independent Research (DFF-1331-00735B)

  • Rasmus O Bak

National Institutes of Health (R01- AI097320)

  • Matthew H Porteus

National Institutes of Health (R01-AI120766)

  • Matthew H Porteus

Stanford Child Health Research Institute (Postdoctoral Award)

  • Daniel P Dever

Austrian Research Council (Erwin Schroedinger Postdoctoral Fellowship)

  • Andreas Reinisch

Amon G. Carter Foundation

  • Matthew H Porteus

Laurie Kraus Lacob Faculty Scholar Award in Pediatric Translational Research (Scholar Award)

  • Matthew H Porteus

National Institutes of Health (PN2EY018244)

  • Matthew H Porteus

Stanford Ludwig Center for Cancer Stem Cell Research

  • Ravindra Majeti

National Institutes of Health (R01-CA188055)

  • Ravindra Majeti

New York Stem Cell Foundation (Robertson Investigator)

  • Ravindra Majeti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal experiments were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The experimental protocol was approved by Stanford University's Administrative Panel on Lab Animal Care (IACUC 25065).

Copyright

© 2017, Bak et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,344
    views
  • 1,722
    downloads
  • 91
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rasmus O Bak
  2. Daniel P Dever
  3. Andreas Reinisch
  4. David Cruz Hernandez
  5. Ravindra Majeti
  6. Matthew H Porteus
(2017)
Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
eLife 6:e27873.
https://doi.org/10.7554/eLife.27873

Share this article

https://doi.org/10.7554/eLife.27873

Categories and tags

Research organisms

Further reading

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine

    Modeling corticotroph deficiency with pituitary organoids supports the functional role of NFKB2 in human pituitary differentiation

    Thi Thom Mac, Teddy Fauquier ... Thierry Brue
    Research Article

    Deficient Anterior pituitary with common Variable Immune Deficiency (DAVID) syndrome results from NFKB2 heterozygous mutations, causing adrenocorticotropic hormone deficiency (ACTHD) and primary hypogammaglobulinemia. While NFKB signaling plays a crucial role in the immune system, its connection to endocrine symptoms is unclear. We established a human disease model to investigate the role of NFKB2 in pituitary development by creating pituitary organoids from CRISPR/Cas9-edited human induced pluripotent stem cells (hiPSCs). Introducing homozygous TBX19K146R/K146R missense pathogenic variant in hiPSC, an allele found in congenital isolated ACTHD, led to a strong reduction of corticotrophs number in pituitary organoids. Then, we characterized the development of organoids harboring NFKB2D865G/D865G mutations found in DAVID patients. NFKB2D865G/D865G mutation acted at different levels of development with mutant organoids displaying changes in the expression of genes involved on pituitary progenitor generation (HESX1, PITX1, LHX3), hypothalamic secreted factors (BMP4, FGF8, FGF10), epithelial-to-mesenchymal transition, lineage precursors development (TBX19, POU1F1) and corticotrophs terminal differentiation (PCSK1, POMC), and showed drastic reduction in the number of corticotrophs. Our results provide strong evidence for the direct role of NFKB2 mutations in the endocrine phenotype observed in patients leading to a new classification of a NFKB2 variant of previously unknown clinical significance as pathogenic in pituitary development.

    1. Stem Cells and Regenerative Medicine

    The Jag2/Notch1 signaling axis promotes sebaceous gland differentiation and controls progenitor proliferation

    Syeda Nayab Fatima Abidi, Sara Chan ... Christian W Siebel
    Research Article

    The sebaceous gland (SG) is a vital appendage of the epidermis, and its normal homeostasis and function is crucial for effective maintenance of the skin barrier. Notch signaling is a well-known regulator of epidermal differentiation, and has also been shown to be involved in postnatal maintenance of SGs. However, the precise role of Notch signaling in regulating SG differentiation in the adult homeostatic skin remains unclear. While there is evidence to suggest that Notch1 is the primary Notch receptor involved in regulating the differentiation process, the ligand remains unknown. Using monoclonal therapeutic antibodies designed to specifically inhibit of each of the Notch ligands or receptors, we have identified the Jag2/Notch1 signaling axis as the primary regulator of sebocyte differentiation in mouse homeostatic skin. Mature sebocytes are lost upon specific inhibition of the Jag2 ligand or Notch1 receptor, resulting in the accumulation of proliferative stem/progenitor cells in the SG. Strikingly, this phenotype is reversible, as these stem/progenitor cells re-enter differentiation when the inhibition of Notch activity is lifted. Thus, Notch activity promotes correct sebocyte differentiation, and is required to restrict progenitor proliferation.